MANKIND PHARMA Latest Share Price (MANKIND)
TODAY IN ONE LINE
MANKIND rose 1.9% on average volume, outperforming Nifty's -0.3% move, supported by recent strong earnings.
With a market cap of ₹94,039.18 Cr., it trades at a P/E of 45.89. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
MANKIND PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 31.7% YoY
- ●Healthy Operating MarginsOPM is structurally strong at 27.7%
- ●High Promoter HoldingPromoters hold 72.6% skin-in-the-game
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Expensive ValuationTrading at a high P/E ratio of 53.6x
- ●Rising Receivables vs SalesReceivables grew 53.5% outpacing sales growth of 19.0%
Latest MANKIND PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
MANKIND PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for MANKIND PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
MANKIND PHARMA trades at a P/E of 45.89× and P/B of 5.77×, against the Healthcare sector median P/E of 41.12×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
MANKIND PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for MANKIND PHARMA — derived from the latest tape, not yesterday's close.
MANKIND PHARMA last traded at ₹2,280 with an intraday range of ₹2,222–₹2,280 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹2280.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 2415.33 | +135.33 | +5.94% |
| R3 | 2357.33 | +77.33 | +3.39% |
| R2 | 2318.67 | +38.67 | +1.70% |
| R1 | 2299.33 | +19.33 | +0.85% |
| PIVOT | 2260.67 | -19.33 | -0.85% |
| CURRENT | 2280.00 | — | — |
| S1 | 2241.33 | -38.67 | -1.70% |
| S2 | 2202.67 | -77.33 | -3.39% |
| S3 | 2183.33 | -96.67 | -4.24% |
| S4 | 2125.33 | -154.67 | -6.78% |
MANKIND is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹2222–₹2239.1
Trading Above opening range, showing Bullishness
MANKIND PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for MANKIND PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
MANKIND PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹94,039.18 Cr. and reported EPS of ₹13.90.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 12,207 | 14,278 ▲ 17.0% |
| Sales Growth YoY %Derived | 18.12% | 16.96% |
| Other Income | 537 | 359 ▼ 33.2% |
| Total Income | 12,744 | 14,636 ▲ 14.8% |
| 3,489 | 4,052 ▲ 16.1% | |
| Gross ProfitDerived | 8,718 | 10,226 ▲ 17.3% |
| Gross Margin %Derived | 71.42% | 71.62% |
| 5,700 | 6,608 ▲ 15.9% | |
| EBITDA (Operating Profit)Derived | 3,018 | 3,617 ▲ 19.9% |
| OPM %Derived | 24.72% | 25.34% |
| 1,051 | 1,396 ▲ 32.8% | |
| Profit Before Tax (PBT) | 2,504 | 2,321 ▼ 7.3% |
| 510 | 395 ▼ 22.6% | |
| Effective Tax %Derived | 20.36% | 17.00% |
| Profit/Loss from Discontinued Ops | 5 | — ▼ 100.0% |
| Total Profit for Period | 2,011 | 1,938 ▼ 3.6% |
| Less: Non-controlling Interests | 20 | 25 ▲ 24.9% |
| Net Profit (Owner's PAT)Derived | 1,991 | 1,913 ▼ 3.9% |
| Net Profit Margin %Derived | 16.31% | 13.40% |
| PAT Growth YoY %Derived | 4.08% | -3.92% |
| Earnings Per Share (EPS ₹) | 48.26 | 46.34 ▼ 4.0% |
| Diluted Shares Outstanding (Cr) | 41 | 41 ▲ 0.1% |
| Share of Profit from Associates/JVs | 12 | 12 ▼ 4.5% |
| Other Comprehensive Income (Net of Tax) | -8 | 57 ▲ 788.1% |
| Total Expenses (incl. D&A & Interest) | 10,240 | 12,315 ▲ 20.3% |
| Material Cost % of RevenueDerived | 16.52% | 16.03% |
| Employee Cost % of RevenueDerived | 22.06% | 22.30% |
| Other Cost % of RevenueDerived | 24.64% | 23.98% |
| Interest Coverage (x)Derived | 5.58x | 4.27x |
| Period | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|
| Revenue from Operations | 8,749 | 10,335 ▲ 18.1% | 12,207 ▲ 18.1% | 14,278 ▲ 17.0% | |
| Sales Growth YoY %Derived | — | 18.12% | 18.12% | 16.96% | |
| Other Income | 129 | 281 ▲ 118.5% | 537 ▲ 91.1% | 359 ▼ 33.2% | |
| Total Income | 8,878 | 10,616 ▲ 19.6% | 12,744 ▲ 20.1% | 14,636 ▲ 14.8% | |
2,914 | 3,210 ▲ 10.2% | 3,489 ▲ 8.7% | 4,052 ▲ 16.1% | ||
| Gross ProfitDerived | 5,836 | 7,125 ▲ 22.1% | 8,718 ▲ 22.4% | 10,226 ▲ 17.3% | |
| Gross Margin %Derived | 66.70% | 68.94% | 71.42% | 71.62% | |
3,935 | 4,590 ▲ 16.6% | 5,700 ▲ 24.2% | 6,608 ▲ 15.9% | ||
| EBITDA (Operating Profit)Derived | 1,901 | 2,535 ▲ 33.4% | 3,018 ▲ 19.0% | 3,617 ▲ 19.9% | |
| OPM %Derived | 21.72% | 24.53% | 24.72% | 25.34% | |
370 | 432 ▲ 16.6% | 1,051 ▲ 143.3% | 1,396 ▲ 32.8% | ||
| Profit Before Tax (PBT) | 1,659 | 2,384 ▲ 43.7% | 2,504 ▲ 5.0% | 2,321 ▼ 7.3% | |
362 | 458 ▲ 26.6% | 510 ▲ 11.4% | 395 ▼ 22.6% | ||
| Effective Tax %Derived | 21.80% | 19.19% | 20.36% | 17.00% | |
| Profit/Loss from Discontinued Ops | — | — | 5 | — ▼ 100.0% | |
| Total Profit for Period | 1,310 | 1,942 ▲ 48.3% | 2,011 ▲ 3.6% | 1,938 ▼ 3.6% | |
| Less: Non-controlling Interests | 28 | 29 ▲ 3.8% | 20 ▼ 30.2% | 25 ▲ 24.9% | |
| Net Profit (Owner's PAT)Derived | 1,282 | 1,913 ▲ 49.2% | 1,991 ▲ 4.1% | 1,913 ▼ 3.9% | |
| Net Profit Margin %Derived | 14.65% | 18.51% | 16.31% | 13.40% | |
| PAT Growth YoY %Derived | — | 49.23% | 4.08% | -3.92% | |
| Earnings Per Share (EPS ₹) | 32.00 | 47.75 ▲ 49.2% | 48.26 ▲ 1.1% | 46.34 ▼ 4.0% | |
| Diluted Shares Outstanding (Cr) | 40 | 40 ▲ 0.0% | 41 ▲ 3.0% | 41 ▲ 0.1% | |
| Share of Profit from Associates/JVs | 12 | 15 ▲ 22.5% | 12 ▼ 19.5% | 12 ▼ 4.5% | |
| Other Comprehensive Income (Net of Tax) | -2 | -8 ▼ 324.9% | -8 ▼ 3.4% | 57 ▲ 788.1% | |
| Total Expenses (incl. D&A & Interest) | 7,219 | 8,231 ▲ 14.0% | 10,240 ▲ 24.4% | 12,315 ▲ 20.3% | |
| Material Cost % of RevenueDerived | 20.73% | 17.93% | 16.52% | 16.03% | |
| Employee Cost % of RevenueDerived | 21.93% | 22.01% | 22.06% | 22.30% | |
| Other Cost % of RevenueDerived | 23.05% | 22.40% | 24.64% | 23.98% | |
| Interest Coverage (x)Derived | 35.41x | 63.73x | 5.58x | 4.27x |
MANKIND PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at MANKIND PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
MANKIND PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for MANKIND PHARMA.
Our AI distills the core fundamental drivers supporting MANKIND PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
MANKIND PHARMA's investment case rests on 0 positive markers and 1 flagged concerns drawn from the latest reported filings.
What you're getting.
No strengths or opportunities on record.
Key Risks.
SWOT generation temporarily unavailable due to model error. The security token included in the request is invalid.
Flip Conditions.
Valuation risk. a P/E above 60 (~1.5× the sector multiple of 41.1) would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
MANKIND PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — MANKIND PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
MANKIND PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for MANKIND PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
MANKIND PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for MANKIND PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in MANKIND PHARMA stood at 71.5% of traded volume, against a 20-day average of 58.6%.
MANKIND PHARMA announcements: results, concalls, ratings, M&A.
Filings MANKIND PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
MANKIND PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 200 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Mankind Pharma Limited has informed the Exchange about Schedule of meet
General Updates
Update on Voluntary Liquidation of Bharat Serums and Vaccines Limited, a WOS.
ESOP/ESOS/ESPS
Mankind Pharma Limited has informed the Exchange regarding Allotment of 49112 Shares.
General Updates
Mankind Pharma Limited has informed the Exchange about General Updates
Cessation
Mankind Pharma Limited has informed the Exchange regarding Cessation of Mr Bharat Anand as Non- Executive Independent Director of the company w.e.f.…
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
MANKIND PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue MANKIND PHARMA has declared, sequenced by announce and record date.
MANKIND PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About MANKIND PHARMA: business, sector, key facts.
What MANKIND PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
MANKIND PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: MANKIND, BSE: 543904.
Mankind Pharma is a prominent Indian pharmaceutical and consumer healthcare company established in 1991 and headquartered in New Delhi. Its core business revolves around the development, manufacturing, and marketing of a diverse range of pharmaceutical formulations and consumer healthcare products, primarily within India but with an expanding international presence. The company's pharmaceutical offerings cater to a wide spectrum of therapeutic areas, encompassing acute and chronic conditions.
A significant portion of Mankind Pharma's pharmaceutical portfolio addresses major health concerns such as infections, cardiovascular issues, gastrointestinal problems, diabetes, dermatological conditions, pain management, neurological disorders, and respiratory illnesses. This extensive range reflects a commitment to providing treatments for a broad array of health needs. The company's strength lies in its ability to develop and manufacture pharmaceuticals across various therapeutic classes.
Beyond pharmaceuticals, Mankind Pharma also has a robust consumer healthcare division. This segment focuses on products designed for over-the-counter use and self-care. Key offerings include male condoms under the Manforce brand, pregnancy detection kits (Prega News), emergency contraceptives (Unwanted-72), antacids (Gas-O-Fas), nutritional supplements, and acne treatments (AcneStar). These consumer products demonstrate the company's commitment to addressing a wider range of health and wellness needs for consumers.
Mankind Pharma's business activities extend beyond its core pharmaceutical and consumer healthcare operations. The company is involved in the trade and export of pharmaceutical and healthcare products, indicating a global reach. Furthermore, it engages in the manufacturing of various materials, including packaging materials, bulk drugs, and consumer goods. This diversification also includes ventures into real estate, leasing, hospitality, and IT services, suggesting a broader business strategy beyond healthcare.
In summary, Mankind Pharma's business model is characterized by its diversified portfolio spanning pharmaceuticals for various therapeutic areas, a substantial consumer healthcare division, and additional ventures in related sectors. The company's success stems from its integration of research, development, manufacturing, and marketing capabilities, coupled with its diverse product offerings and strategic diversification into other businesses.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about MANKIND PHARMA (MANKIND).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of MANKIND PHARMA (MANKIND)?
The current share price of MANKIND PHARMA (MANKIND) is ₹2,280.00. Today, the stock has gained by ₹41.60 (1.86%), trading in a range of ₹2,222.00 to ₹2,280.00. The stock opened at ₹2,237.20 with a trading volume of 5,30,698 shares.
02Is MANKIND PHARMA stock a good investment for long-term?
MANKIND PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹94,039.18 Cr., P/E ratio of 45.89, ROE of 12.41%, and ROCE of 11.87%. The dividend yield stands at 0%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of MANKIND PHARMA stock?
The 52-week high price of MANKIND PHARMA (MANKIND) is ₹2,674.00, while the 52-week low is ₹1,909.70. Currently trading at ₹2,280.00, the stock is 19.39% above its 52-week low and 14.73% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy MANKIND PHARMA stock at the current price?
Whether to buy MANKIND PHARMA stock at ₹2,280.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 45.89 and P/B ratio of 5.77. Today's performance shows a gain of 1.86%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of MANKIND PHARMA and when is the next dividend?
MANKIND PHARMA offers a dividend yield of 0%, which means for every ₹100 invested at the current price of ₹2,280.00, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of MANKIND PHARMA?
MANKIND PHARMA's key financial metrics include: P/E Ratio: 45.89, P/B Ratio: 5.77, ROE: 12.41%, ROCE: 11.87%, Dividend Yield: 0%, EPS: ₹13.90, Book Value: ₹401.00, and Debt-to-Equity: 0.34. The company's market cap stands at ₹94,039.18 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is MANKIND PHARMA stock performing today in the market?
MANKIND PHARMA stock opened at ₹2,237.20 and is currently trading at ₹2,280.00, showing a gain of ₹41.60 (1.86%). The intraday high is ₹2,280.00 and low is ₹2,222.00. The trading volume stands at 5,30,698 shares, indicating moderate market participation today.
08What is the P/E ratio of MANKIND PHARMA and what does it indicate?
MANKIND PHARMA has a Price-to-Earnings (P/E) ratio of 45.89, which means investors are willing to pay 45.89 for every ₹1 of earnings. With an EPS of ₹13.90, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about MANKIND PHARMA (MANKIND) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.